Plan a mechanism-of-action (MOA) animation as a claim, not as decoration: every scene should show only what the device’s FDA-required labeling and the company’s evidence support, for the indication, patient population and directions for use in that labeling. FDA judges a device’s intended uses by objective intent, which advertising can show (21 CFR 801.4), so a medical device animation that pictures another use can create an off-label problem without a word of voiceover. Build a reference for every scene, have medical, regulatory and legal reviewers sign off the boards, the animatic and the final cut, and control versions so the approved cut is the one that ships.
This article explains why the pictures count, what FDA and the FTC have published about labeling consistency and evidence, and how to run the review scene by scene. It describes the rules so the schedule can make room for them. It is not legal advice: the manufacturer’s regulatory and legal reviewers decide what the animation may show and say.
Why a medical device animation counts as a claim
A mechanism animation tells viewers what a device does, where in the body it acts, for whom, how fast and with what result. Each of those is a representation about the product, and regulators read pictures as well as words. The animation is therefore reviewed like copy, frame by frame.
Labeling, advertising and the pictures in both
The FD&C Act defines labeling as “all labels and other written, printed, or graphic matter” upon a device or its containers or “accompanying such article”. FDA’s Device Labeling page explains that “accompanying” is “interpreted liberally to mean more than physical association with the product”, and quotes an appellate court: “Most, if not all advertising, is labeling.”
Responsibility is split between two agencies. FDA’s June 2018 guidance on labeling-consistent communications notes that FDA’s authority “includes oversight of labeling for all drugs and devices and of advertising for prescription drugs and restricted devices” (FDA, CFL guidance). The FTC’s Health Products Compliance Guidance (December 2022) puts it from the other side: “The FDA has primary responsibility for claims that appear in labeling”, while the FTC has primary responsibility for claims in all forms of advertising.
Which category a particular video falls into (labeling, advertising, or both) is a question for your regulatory team. For planning, the safer assumption is that the animation will be read by one agency or the other, and that both will look at the pictures.
Images carry meaning on their own
The FTC asks marketers to assess the “net impression” conveyed by all elements of an ad, including “the text, product name, and any charts, graphs, and other images”. Its guidance gives the example of a brochure with doctors in white lab coats looking through microscopes: the images “give an impression of scientific legitimacy” and suggest the product has been clinically proven. A mechanism animation is full of such signals. A glowing target tissue, a counter ticking up, a molecule docking with a satisfying click: each can say more than the script does.
Intended use: how pictures can imply a use the device is not cleared for
FDA reads a device’s intended uses from what the manufacturer’s materials show, not only from what they say. An animation that places the device on another body site, in another patient group or in another setting can point to a use outside the labeling.
What 21 CFR 801.4 says
The regulation defines intended uses as “the objective intent of the persons legally responsible for the labeling” of a device. That intent “may be shown by such persons’ expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article”, and “may, for example, be shown by labeling claims, advertising matter, or oral or written statements”. The current text dates from an August 2021 amendment, and it adds that a firm is not regarded as intending an unapproved new use for a device that is approved, cleared, granted marketing authorization or exempt “based solely on that firm’s knowledge that such device was being prescribed or used by health care providers for such use”.
The phrase “advertising matter” is the one to tape to the edit suite. Advertising is a recognized way of showing intent, and an animation is advertising matter as much as a brochure is.
Clearance pathways and what the labeling covers
Devices fall into Class I, II or III, with regulatory control rising from I to III. FDA’s Overview of Device Regulation explains that most Class I devices are exempt from premarket notification, most Class II devices require a 510(k), and most Class III devices require premarket approval (PMA). The pathway matters to the animation because it decides what the FDA-required labeling contains: for a PMA device, the labeling approved in that review; for a 510(k) or exempt device, the labeling that provides adequate directions for use and the other required information.
Ask your regulatory team for the current labeling, the indications for use, the instructions for use and any device description, before the script is written. Those documents are the brief for every scene.
Scene elements that imply a use
| What a scene shows | What it can imply | Check it against |
|---|---|---|
| The device acting on a body site | An indication for that site | Indications for use |
| The patient drawn (age, sex, body type, condition) | The population the device is for | Indications, contraindications |
| The setting (clinic, home, ambulance, gym) | Who uses it and where | Directions for use, any use-setting limits |
| Session length, frequency, number of applications | A use regimen | Directions for use |
| What happens to tissue after use | An effect, often a clinical outcome | Labeling and the study data |
| The device beside another product | Use with that product, or a comparison | Labeling; comparative evidence |
| A before-and-after split | A demonstrated result | Study data and its limitations |
The table is a checklist, not a verdict. A scene can show a home setting and be entirely consistent with the labeling, if the labeling covers home use. The point is that someone checks each element against a named document, and writes down which one.
What “consistent with the FDA-required labeling” means for mechanism content
FDA’s June 2018 final guidance sets out how the agency evaluates firms’ communications that present information not in the labeling but consistent with it. Mechanism of action is one of its examples, which makes it the most directly useful FDA text for planning an MOA animation.
Scope and status
The guidance covers drugs, biologics, animal drugs and devices. For devices, it treats approval and clearance as covering the PMA, 510(k), De Novo and Humanitarian Device Exemption pathways, and devices exempt from premarket notification. Like FDA guidance generally, it states that it does not “establish legally enforceable responsibilities”; it describes the agency’s current thinking. Your regulatory team decides how it applies to your device.
The three factors
FDA uses three factors to decide whether a communication is consistent with the FDA-required labeling, and “if a product communication fails to satisfy any one of these factors, it is not considered consistent”. In summary:
- How the information compares with the labeling’s conditions of use. Four questions: does it relate to a different indication, a patient population outside the labeling, a use that conflicts with the limitations or directions for handling and use, or a different dosing or use regimen or route of administration?
- Whether the representations increase the potential for harm to health relative to the labeling, for example by introducing new risks or raising the rate or severity of known ones.
- Whether the labeling’s directions for use enable the product to be used safely and effectively under the conditions the communication shows.
| Factor 1 question (FDA) | Where it shows up in an animation | Example of a scene to check |
|---|---|---|
| Indication: a different indication than the labeling? | The body site, the condition drawn, the effect shown | The device animated on a joint the labeling does not mention |
| Patient population: outside the labeling? | The patient character, captions, voiceover | A child drawn for a device labeled for adults |
| Limitations and directions for handling and use: in conflict? | Setting, who operates the device, steps shown | A patient using alone a device labeled for use by a clinician |
| Dosing or use regimen, administration: in conflict? | Session timers, repetitions, time-lapse, route or placement | Two sessions a day animated where the directions say one |
Mechanism of action is named
Among its examples of information that may be consistent with the labeling, the guidance lists “information that provides additional context about the mechanism of action described in the FDA-required labeling”. That is an encouraging line for MOA work, with a condition attached: the mechanism the animation elaborates should be the one the labeling describes. If the labeling says nothing about how the device works, the mechanism in the animation is new information, and it needs its own support.
Device examples in the guidance
The guidance uses device examples on both sides of the line. As information that may be consistent with the labeling, it describes a prosthetic hip, approved to treat mobility-limiting joint disease caused by osteoarthritis, whose firm presents the device’s effect on symptoms such as decreased hip pain at an interim point before the primary endpoint; and a vascular interventional device whose firm presents procedure-related pain for patients treated for the approved use. As information that is not consistent, it describes a diagnostic device indicated as an aid in managing patients already diagnosed with an infection, promoted for making an initial diagnosis in previously undiagnosed patients.
Translated into animation: showing more about what the device does for its labeled patients, in its labeled use, can sit inside the labeling. Showing the same device doing a different job for a different group does not, however accurate the drawing is.
How much evidence a mechanism scene needs
The guidance says representations “need to be grounded in fact and science and presented with appropriate context”, and that supporting data “should be scientifically appropriate and statistically sound”. It also says the amount and type of evidence depends on the topic: “different evidence would be needed to support a long-term efficacy presentation than would be needed to support a presentation about a product’s mechanism of action.”
Two further points from the guidance affect animation directly. First, disclosing the limitations of a weak study “does not correct the misleading message” if the study cannot support what is shown. Second, FDA looks at “the overall impression created by the communication as a whole”, and judges prominence by factors including “location, font size, contrast, and white space”, which is the language of on-screen supers.
The guidance adds that if the labeling contains data related to what the communication presents, the communication should include that labeling information too, “to provide the audience with appropriate context”. For an MOA film that shows, say, how a device distributes pressure, the reviewers will ask whether the labeling’s own figures belong on screen beside the animation.
The guidance also flags a limit for cleared devices: communications about a 510(k)-cleared or exempt device that change its intended use so significantly that a PMA or De Novo would be the appropriate submission are not consistent with the labeling. An animation that turns a device for one purpose into the hero of another is the visual form of that problem.
Evidence behind every frame: the FTC standard and the net impression
For advertising outside FDA’s direct jurisdiction, the FTC expects health claims to be backed by “competent and reliable scientific evidence”, and it reads claims from the whole ad, pictures included. An animation that looks like proof can be a claim of proof.
The standard
The FTC’s guidance defines competent and reliable scientific evidence as “tests, analyses, research, or studies that (1) have been conducted and evaluated in an objective manner by experts” in the relevant field and are “generally accepted in the profession to yield accurate and reliable results”, and that are “sufficient in quality and quantity based on standards generally accepted in the relevant scientific fields”. It applies to every objective product claim conveyed “expressly or by implication”, and the guidance holds a marketer responsible for claims “suggested or reasonably implied” in advertising.
Disclaimers do not rescue a misleading picture
The guidance’s section on clear and conspicuous disclosures says a disclosure “can’t directly contradict a claim”. Its Example 15 describes a website for an unproven product that uses medical imagery and terminology, with a fine-print statement that no clinical study has been performed; the FTC says the site “conveys a false claim that the product’s efficacy is backed by scientific proof”, and the fine print does not fix it because it contradicts the claim and is not clear and conspicuous. When a claim is made both visually and audibly, the guidance says the disclosure should be made “both visually and audibly” too.
For animation, that means an on-screen “Illustration” or “Simulated” label qualifies a picture, but it cannot reverse what the picture plainly shows. If the frame shows a result the evidence does not support, the frame changes.
“FDA approved” and cleared devices
Clearance is not approval. FDA’s regulation on premarket notification says a substantial-equivalence determination “does not in any way denote official approval of the device”, and “any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding” (21 CFR 807.97). The FTC’s guidance, under “Mischaracterizations of FDA approval”, gives the example of a belt cleared as a Class II device for muscle stimulation whose infomercial called it “FDA Approved” next to weight-loss claims; the FTC treats the combination as deceptive because the clearance did not cover those results.
In animation, this shows up as graphics: a seal, a badge, a shield with a check mark, an end card that pairs the agency’s name with a result. Every reference to FDA status is written by your regulatory team and placed where they decide.
Visual shorthand that implies proof
| Visual device | What viewers may read into it | Planning note |
|---|---|---|
| Lab coats, microscopes, lab glassware | The product is clinically proven | Use only if the evidence supports that impression |
| A data overlay or rising chart | A measured result | Every number traced to a study; no decorative data |
| Before-and-after split | A demonstrated outcome | Study data, conditions and limitations decided by reviewers |
| Glowing “healed” tissue | A clinical effect | Only effects the labeling and evidence describe |
| Agency seal or check-mark badge | Official approval | Wording and placement from regulatory only |
Accuracy and simplification: deciding what the animation may leave out
Every mechanism animation simplifies: it changes scale, speed, transparency and color so the viewer can see what matters. The review question is not whether a scene is simplified but whether the simplification changes the claim. Keep a simplification log, and have the medical reviewer sign it.
Types of simplification
| Simplification | Example | Usually acceptable when | Record in the log |
|---|---|---|---|
| Scale | A device component enlarged beside tissue | The relative proportions that matter to the claim are kept | Factor and reason |
| Time | A 30-minute session shown in seconds | The regimen is stated in voice or text, so the speed does not imply a shorter session | Real duration, screen duration, factor |
| Transparency and cutaway | Skin made transparent to show a vessel | The structure shown is anatomically correct | Reference used |
| Color coding | Pressure shown as a color gradient | The legend is on screen and the gradient matches measured data, or is labeled as illustrative | Data source or “illustrative” |
| Omission | Surrounding structures left out | Nothing omitted would change how the mechanism works or its risks | What was left out and why |
| Idealized anatomy | One average anatomy for all patients | The labeled population is represented | Population reference |
Schematic or photoreal
The visual style is a claim decision too. A schematic look (flat color, clear outlines, labeled parts) tells viewers they are watching a diagram. A photoreal look can be read as imaging of a real patient. Neither is wrong, but photoreal tissue showing an effect raises the evidence bar for what that tissue does. 2D animation suits schematic explanation and data; 3D and CGI suits device geometry and spatial relationships, and many MOA films use both.
Device geometry from CAD
The device itself should be built from engineering files, so its proportions, parts and motion are right. That handoff (files, tessellation, finishes, the parts that may be shown, and who signs for accuracy) is covered in from CAD to product animation. For a medical device, the parts that move in the MOA animation are usually the claim, so the engineering accuracy check and the regulatory check meet in the same shots.
Example (fictional). Brisemont is an invented maker of a wearable compression sleeve, not a client, and its labeling here is invented for the example. In this example, the labeling covers one indication, for adults, used in a clinic, in sessions of up to 30 minutes. The first storyboard for a 60-second mechanism animation has four scenes the regulatory reviewer flags. Scene 2 draws a teenage patient (patient population). Scene 4 shows the sleeve used in a bedroom (use setting). Scene 6 is a time-lapse of tissue “recovering” over four weeks (an outcome the labeling and evidence do not describe). Scene 5 compresses a 30-minute session into 6 seconds: 30 x 60 = 1,800 seconds, and 1,800 / 6 = 300 times real speed, or 6 x 24 = 144 frames at 24 fps. Scenes 2, 4 and 6 are redrawn with an adult, a clinic and no outcome sequence. Scene 5 stays, logged as a time simplification, with the voiceover stating “a 30-minute session” so the speed does not imply a shorter regimen.
Restricted devices, prescription drugs and scientific exchange
Some products carry extra requirements that change what the animation must include or where it may be shown. Your regulatory team will know whether any apply; the plan should ask on day one.
Restricted devices
For a restricted device, the FD&C Act makes the device misbranded if “its advertising is false or misleading in any particular”, and requires all advertisements and other descriptive printed matter to include the device’s established name, printed prominently “in type at least half as large as that used for any trade or brand name”, and “a brief statement of the intended uses of the device and relevant warnings, precautions, side effects, and contraindications” (FD&C Act sections 502(q) and 502(r), 21 U.S.C. 352). How a brief statement is presented in a video (on screen, in voice, for how long) is a decision for your reviewers, and the edit has to make room for it.
Prescription drugs and combination products
If the brand also advertises a prescription drug on TV or radio, FDA’s final rule on the “major statement” applies to those ads. Published November 21, 2023, it took effect May 20, 2024, with compliance required from November 20, 2024 (Federal Register, 2023-25428). It sets five standards for presenting side effects and contraindications in a clear, conspicuous and neutral manner: consumer-friendly language; audio at least as understandable as the rest of the ad; in TV ads, the audio presented concurrently in text for long enough to read; text formatted to be read easily; and no audio or visual elements during the major statement that are likely to interfere with comprehension. For an MOA animation inside such an ad, the last standard is the one the animation team feels: busy motion under the major statement is the kind of element the rule addresses. Whether a drug-device combination product falls under these rules is for your regulatory team.
Scientific information on unapproved uses
Sharing scientific information about unapproved uses with health care providers is a separate channel with its own FDA guidance. On January 7, 2025, FDA announced a final guidance on firms’ communications to health care providers of scientific information on unapproved uses of approved or cleared products; the notice said the guidance was “not for current implementation” pending the Office of Management and Budget’s decision on its information collection (Federal Register, 2024-31539). Check its current status on FDA’s guidance pages. The practical point for production is narrower: a promotional MOA animation should not be re-cut for scientific exchange, or the reverse, without going back through review, because the rules for each channel differ.
Broadcast clearance is another review
A spot that will air on TV also goes through the networks’ clearance process, which is separate from your regulatory review; see TV commercial clearance.
| Material | Oversight | Source |
|---|---|---|
| Labeling of any device, including graphic matter accompanying it | FDA | FD&C Act 201(m), as quoted on FDA's Device Labeling page |
| Advertising of restricted devices | FDA; brief statement and established name required | FD&C Act 502(q) and 502(r), 21 U.S.C. 352 |
| Advertising of other devices and health products | FTC has primary responsibility | FTC Health Products Compliance Guidance (December 2022) |
| DTC TV and radio ads for prescription drugs | FDA; major statement standards since November 20, 2024 | Final rule, Federal Register, November 21, 2023 |
| Any device communication: intended use | FDA reads objective intent, including advertising matter | 21 CFR 801.4 |
Audiences: what changes between HCP and patient versions
The mechanism is the same for every audience, but the depth, language and placement change, and each version is reviewed for its own audience. Decide the audiences in the plan, because they multiply the files and the reviews.
Health care providers
A version for clinicians can carry more anatomy, more precise terminology and study data on screen, with the study design and limitations the guidance asks firms to disclose (type of study, objectives, use regimen, controls and the population studied). It may be shown at congresses, in training or by sales teams, where it can be paused and questioned. The reference matrix matters most here, because a clinician will ask where a detail comes from.
Patients and consumers
A patient version explains the same mechanism in plain language, with fewer numbers and more attention to what the patient will see and feel during use. Simplifications are larger, so the simplification log grows. Any person on screen who appears to be a patient or clinician needs a portrayal decision from legal: an actor, a real patient with a release, or a drawn character, each labeled as your reviewers decide.
Placement decides the real audience
A video posted on a public product page reaches patients, caregivers and clinicians alike, whatever audience it was made for. If a version is meant only for clinicians, the plan should say where it will live and who can reach it, and the reviewers should judge it on the audience it will actually find. A cut for one placement should not drift into another without review; the re-review triggers below include a change of placement for that reason.
The review workflow, scene by scene
Review a mechanism animation at the stages where changes are cheap: the script, the boards, the animatic and the greycard. By the final render, the only acceptable notes should be small ones. Each stage has a named reviewer, a reference matrix that travels with the files, and a date in the schedule.
The reference matrix
The reference matrix is one row per scene. It lists what the scene shows and says; the source for each element (labeling section, instructions for use page, study, anatomy reference, CAD revision); the simplifications from the log; any super or disclosure and its on-screen duration; and the reviewer who signed it, with the date. It answers the question every reviewer asks (“where does this come from?”) before it is asked, and it becomes the approval record at the end.
FDA’s labeling-consistency guidance recommends that, before a firm disseminates such a communication, “qualified medical/scientific, legal, and regulatory personnel carefully review the communication to ensure it is not false or misleading”. The matrix is how that review is done on a moving picture rather than a page.
Example (fictional). Three rows of Brisemont’s reference matrix (the invented sleeve maker above; document names and sections are invented):
| Scene (in to out) | What it shows | Source | Simplification | Super or statement | Signed |
|---|---|---|---|---|---|
| 3 (14 to 22 s) | Chambers inflate in sequence from ankle to knee | Device description, instructions for use rev. C section 2; CAD rev. F | Sleeve fabric transparent | None | Medical, engineering |
| 5 (30 to 36 s) | One session, sped up | Directions for use, rev. C section 4 | Time, 300 times real speed | Voiceover: “a 30-minute session” | Medical, regulatory |
| 7 (50 to 60 s) | End card with product name and indication | Labeling, indications for use | None | Indication super, held 4 s | Regulatory, legal |
Stages and sign-offs
The stages map onto the production order on how we work: the claims list and reference matrix start in Plan, the script, boards, style frames and animatic come in Develop, the greycard and renders in Make, the final cut in Finish and the cutdowns in Version. Storyboards, animatics and previs are explained in depth in storyboards, animatics and previs; for an MOA film the difference is who sits in the review.
Who reviews what
- Medical or scientific reviewer: anatomy, physiology, device interaction with tissue, every simplification in the log.
- Regulatory reviewer: consistency with the labeling (indication, population, directions, regimen), FDA status wording, required statements.
- Legal reviewer: claims and substantiation, comparisons, trademarks, portrayal labels, music and talent rights.
- Engineering: device geometry, motion and the CAD revision.
- Brand: look, voice and the end card.
FDA’s guidance names the first three disciplines together. Whether they review in one meeting or in sequence, the plan names people, not departments, and gives each review a number of working days.
Review time in the schedule
Review is the part of an MOA schedule that production cannot compress. Ask each reviewer how many working days a round takes, add them up, and put the total in the plan before anyone promises a launch date.
Example (fictional). Brisemont’s reviewers ask for 5 working days each for the script, the boards, the animatic and the final cut, 3 for the greycard and 3 for the versions: 5 + 5 + 5 + 3 + 5 + 3 = 26 working days, or 5.2 five-day weeks of a 12-week schedule spent waiting for decisions. The plan runs other work in parallel where it can (music search during the board review, look development during the animatic review) and states that a second round at any stage adds that stage’s days again.
Timing supers and required statements
Required statements take screen time. A super that must be read needs enough frames at a legible size in every aspect ratio, and a statement in the voiceover needs seconds in the script. The script timing calculator estimates how many words fit a given length at a given pace. Plan the space at the script stage, because a required statement added at the final cut usually means re-timing the animation underneath it.
Version control: the approved cut is the one that ships
The approval record belongs to a specific file. If anything in that file changes after sign-off, the change goes back to the reviewer who owns that element, however small it looks. Version control is what makes the sign-off mean something on the day the file is uploaded.
What the approval record holds
For each master and each version: the file name and version number; length and frame count; aspect ratio; language; the reference matrix version it was reviewed against; the labeling version it was checked against; the reviewers, their decisions and dates; and a checksum of the approved file, so the file that is trafficked can be compared byte for byte with the one that was approved.
Re-review triggers
| Change | Why it goes back to review | Who reviews |
|---|---|---|
| Labeling or instructions for use revised | Every scene was checked against the old version | Regulatory first, then all |
| New clearance or new indication | Scenes may now be allowed, or need new statements | Regulatory, legal |
| New study or new data shown | Evidence and its limitations change | Medical, legal |
| New placement or audience (HCP to patient) | What is appropriate and required differs by audience | Regulatory, legal |
| Cutdown or new aspect ratio | A crop can drop a super or show a scene without its context | Regulatory |
| Translation | Claims and statements change wording | Regulatory, legal, a native-speaker reviewer |
| Music, voice or color fix after approval | Can change emphasis or the legibility of a super | The owner of that element |
Cutdowns and crops
A 15-second cutdown is not a shorter copy of the 60. It may drop the scene that carried a required statement, or show a mechanism scene without the setup that made it accurate. A 9:16 crop can push a super out of frame or behind a platform’s interface. Each version is reviewed as its own file, against the same reference matrix. Campaign versioning and the deliverables page describe how versions are named and checked.
Example (fictional). Brisemont (the invented sleeve maker above) plans an HCP version and a patient version, each at 60, 30 and 15 seconds, in 16:9, 1:1 and 9:16. That is 2 audiences x 3 lengths x 3 ratios = 18 masters, each with its own approval record and checksum. Six months after launch, in this example, the instructions for use are revised to change one cleaning step that appears only in the 60- and 30-second cuts. All 18 files go back to the regulatory reviewer. The 12 longer files (2 x 2 x 3) are re-edited and re-reviewed; the 6 fifteen-second files (2 x 1 x 3) are confirmed unaffected, and that confirmation is recorded against the new labeling version.
At handover
The handover package should include the approved masters, the approval records, the final reference matrix and simplification log, caption files, and the rights sheet listing talent, music and stock terms. If any AI-assisted step was used in production, the provenance log lists the step, the shot and the person who reviewed it, as described in Blendpipe’s AI practices.
Checklist before the first storyboard
Gather these before the script is written, and the review will have something to review against.
From regulatory
- The current FDA-required labeling, indications for use and instructions for use, with version numbers
- The device’s pathway and class, and whether it is a restricted device
- The approved wording for any reference to FDA status
- Required statements, with their wording and how they must appear
From medical and scientific
- The mechanism as the labeling describes it, and the evidence for any added detail
- Anatomy and physiology references for every body structure shown
- The studies behind any number, chart or outcome, with their limitations
From engineering
- CAD at a named revision, the parts that may be shown, and motion limits
From legal and brand
- Claims already approved for other materials, and their substantiation
- Portrayal labels for actors, and talent and music terms
- Brand look, and a decision on schematic or photoreal style
For the plan
- Named reviewers for each stage and the working days each needs
- Placements and audiences (HCP, patient, consumer), lengths, ratios and languages
- Where the film will run, including any broadcast use
For an overview of how a production plan handles claims lists, review steps and portrayal labels for health brands, see healthcare and wellness. When the labeling, references and reviewers are in hand, send a brief with the placements and the date the first version must be live.
